CAP V Mauritius Limited managed by The Carlyle Group Inc. (NasdaqGS:CG) agreed to acquire 5% stake in Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) for CNY 1.8 billion on September 1, 2020. Qiuning (Frank) Sun of Latham & Watkins acted as the legal advisor to the Carlyle Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.58 USD | -0.95% | -11.05% | -0.27% |
02/05 | Deutsche Bank Adjusts Carlyle Group Price Target to $55 From $63, Maintains Buy Rating | MT |
02/05 | Oppenheimer Adjusts Carlyle Group Price Target to $68 From $74, Maintains Outperform Rating | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.27% | 14.72B | |
-9.11% | 84.86B | |
+17.24% | 84.18B | |
+13.22% | 25.63B | |
-6.09% | 17.39B | |
+8.20% | 14.28B | |
-22.89% | 11.98B | |
+22.88% | 9.96B | |
+21.54% | 8.68B | |
+21.00% | 7.12B |
- Stock Market
- Equities
- CG Stock
- News The Carlyle Group Inc.
- CAP V Mauritius Limited managed by The Carlyle Group Inc. (NasdaqGS: CG) agreed to acquire 5% stake in Shenzhen Salubris Pharmaceuticals Co., Ltd. for CNY 1.8 billion.